Entera Bio Ltd. Operating Cash Flow

Operating Cash Flow of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Cash Flow growth rates and interactive chart. Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations, otherwise it may require external financing for expansion or even survival. A negative number means the company is funded through external capital (debt or equity issuance) or cash available on the balance sheet. A positive number means that a company generates enough cash to pay for its operations.


Highlights and Quick Summary

  • Operating Cash Flow for the quarter ending June 29, 2020 was $-3.53 Million (a 32.76% increase compared to previous quarter)
  • Year-over-year quarterly Operating Cash Flow increased by 112.67%
  • Annual Operating Cash Flow for 2019 was $-8.92 Million (a -8.95% decrease from previous year)
  • Annual Operating Cash Flow for 2018 was $-9.8 Million (a 116.44% increase from previous year)
  • Twelve month Operating Cash Flow ending June 29, 2020 was $-11 Million (a 14.54% increase compared to previous quarter)
  • Twelve month trailing Operating Cash Flow increased by 36.9% year-over-year
Trailing Operating Cash Flow for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$-11 Million $-9.64 Million $-8.92 Million $-8.07 Million
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Cash Flow of Entera Bio Ltd.

Most recent Operating Cash Flowof ENTX including historical data for past 10 years.

Interactive Chart of Operating Cash Flow of Entera Bio Ltd.

Entera Bio Ltd. Operating Cash Flow for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-3.53 $-2.66
2019 $-3.2 $-1.66 $-2.12 $-1.93 $-8.92
2018 $-2.35 $-2.24 $-2.74 $-2.47 $-9.8
2017 $-4.53 $-4.53

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.